Cyclosporine elimination in the presence of TOR inhibitors

Effects on renal function, acute rejection, and safety

Jorge A. Velosa, Timothy S. Larson, James M. Gloor, Mark D Stegall

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Sirolimus in combination with cyclosporine reduces the incidence of acute rejection in renal transplant recipients when administered in double- or triple-therapy immunosuppressive regimens. Sirolimus administered as primary therapy has a beneficial effect on renal function, and the frequency of rejection episodes is similar to that of primary immunosuppression with cyclosporine. A strategy that may result in a more benign immunologic course with a substantially beneficial effect on renal function is to administer sirolimus and a calcineurin inhibitor early after transplantation, thereby promoting immunologic adaptation, and then to withdraw the calcineurin inhibitor at some point after transplantation to prevent nephrotoxicity. This article examines the results of this approach in recent studies that evaluated the effect of cyclosporine withdrawal on renal function, acute rejection, and safety in patients treated with sirolimus. Two open-label randomized trials of cyclosporine withdrawal were conducted in the United States, Canada, Europe, and Australia. In one of the studies, graft survival, patient survival, and the incidence of acute rejection at 6 months posttransplantation were not statistically significantly different between the patients receiving cyclosporine and the group that had undergone cyclosporine withdrawal. Furthermore, significantly better renal function was observed in the patients who underwent cyclosporine withdrawal compared with patients who continued to receive full-dose cyclosporine. These studies indicate that cyclosporine withdrawal has a beneficial effect on renal function without a significant increase in the incidence of acute rejection episodes.

Original languageEnglish (US)
JournalAmerican Journal of Kidney Diseases
Volume38
Issue number4 SUPPL. 2
StatePublished - 2001

Fingerprint

Cyclosporine
Kidney
Safety
Sirolimus
Incidence
Transplantation
Graft Survival
Patient Safety
Immunosuppressive Agents
Immunosuppression
Canada
Survival
Therapeutics

Keywords

  • Acute rejection
  • Cyclosporine
  • Renal function
  • Sirolimus
  • Target of rapamycin (TOR) inhibitors

ASJC Scopus subject areas

  • Nephrology

Cite this

Cyclosporine elimination in the presence of TOR inhibitors : Effects on renal function, acute rejection, and safety. / Velosa, Jorge A.; Larson, Timothy S.; Gloor, James M.; Stegall, Mark D.

In: American Journal of Kidney Diseases, Vol. 38, No. 4 SUPPL. 2, 2001.

Research output: Contribution to journalArticle

@article{9618a8dd9fad4744a9d513e8eb108aa1,
title = "Cyclosporine elimination in the presence of TOR inhibitors: Effects on renal function, acute rejection, and safety",
abstract = "Sirolimus in combination with cyclosporine reduces the incidence of acute rejection in renal transplant recipients when administered in double- or triple-therapy immunosuppressive regimens. Sirolimus administered as primary therapy has a beneficial effect on renal function, and the frequency of rejection episodes is similar to that of primary immunosuppression with cyclosporine. A strategy that may result in a more benign immunologic course with a substantially beneficial effect on renal function is to administer sirolimus and a calcineurin inhibitor early after transplantation, thereby promoting immunologic adaptation, and then to withdraw the calcineurin inhibitor at some point after transplantation to prevent nephrotoxicity. This article examines the results of this approach in recent studies that evaluated the effect of cyclosporine withdrawal on renal function, acute rejection, and safety in patients treated with sirolimus. Two open-label randomized trials of cyclosporine withdrawal were conducted in the United States, Canada, Europe, and Australia. In one of the studies, graft survival, patient survival, and the incidence of acute rejection at 6 months posttransplantation were not statistically significantly different between the patients receiving cyclosporine and the group that had undergone cyclosporine withdrawal. Furthermore, significantly better renal function was observed in the patients who underwent cyclosporine withdrawal compared with patients who continued to receive full-dose cyclosporine. These studies indicate that cyclosporine withdrawal has a beneficial effect on renal function without a significant increase in the incidence of acute rejection episodes.",
keywords = "Acute rejection, Cyclosporine, Renal function, Sirolimus, Target of rapamycin (TOR) inhibitors",
author = "Velosa, {Jorge A.} and Larson, {Timothy S.} and Gloor, {James M.} and Stegall, {Mark D}",
year = "2001",
language = "English (US)",
volume = "38",
journal = "American Journal of Kidney Diseases",
issn = "0272-6386",
publisher = "W.B. Saunders Ltd",
number = "4 SUPPL. 2",

}

TY - JOUR

T1 - Cyclosporine elimination in the presence of TOR inhibitors

T2 - Effects on renal function, acute rejection, and safety

AU - Velosa, Jorge A.

AU - Larson, Timothy S.

AU - Gloor, James M.

AU - Stegall, Mark D

PY - 2001

Y1 - 2001

N2 - Sirolimus in combination with cyclosporine reduces the incidence of acute rejection in renal transplant recipients when administered in double- or triple-therapy immunosuppressive regimens. Sirolimus administered as primary therapy has a beneficial effect on renal function, and the frequency of rejection episodes is similar to that of primary immunosuppression with cyclosporine. A strategy that may result in a more benign immunologic course with a substantially beneficial effect on renal function is to administer sirolimus and a calcineurin inhibitor early after transplantation, thereby promoting immunologic adaptation, and then to withdraw the calcineurin inhibitor at some point after transplantation to prevent nephrotoxicity. This article examines the results of this approach in recent studies that evaluated the effect of cyclosporine withdrawal on renal function, acute rejection, and safety in patients treated with sirolimus. Two open-label randomized trials of cyclosporine withdrawal were conducted in the United States, Canada, Europe, and Australia. In one of the studies, graft survival, patient survival, and the incidence of acute rejection at 6 months posttransplantation were not statistically significantly different between the patients receiving cyclosporine and the group that had undergone cyclosporine withdrawal. Furthermore, significantly better renal function was observed in the patients who underwent cyclosporine withdrawal compared with patients who continued to receive full-dose cyclosporine. These studies indicate that cyclosporine withdrawal has a beneficial effect on renal function without a significant increase in the incidence of acute rejection episodes.

AB - Sirolimus in combination with cyclosporine reduces the incidence of acute rejection in renal transplant recipients when administered in double- or triple-therapy immunosuppressive regimens. Sirolimus administered as primary therapy has a beneficial effect on renal function, and the frequency of rejection episodes is similar to that of primary immunosuppression with cyclosporine. A strategy that may result in a more benign immunologic course with a substantially beneficial effect on renal function is to administer sirolimus and a calcineurin inhibitor early after transplantation, thereby promoting immunologic adaptation, and then to withdraw the calcineurin inhibitor at some point after transplantation to prevent nephrotoxicity. This article examines the results of this approach in recent studies that evaluated the effect of cyclosporine withdrawal on renal function, acute rejection, and safety in patients treated with sirolimus. Two open-label randomized trials of cyclosporine withdrawal were conducted in the United States, Canada, Europe, and Australia. In one of the studies, graft survival, patient survival, and the incidence of acute rejection at 6 months posttransplantation were not statistically significantly different between the patients receiving cyclosporine and the group that had undergone cyclosporine withdrawal. Furthermore, significantly better renal function was observed in the patients who underwent cyclosporine withdrawal compared with patients who continued to receive full-dose cyclosporine. These studies indicate that cyclosporine withdrawal has a beneficial effect on renal function without a significant increase in the incidence of acute rejection episodes.

KW - Acute rejection

KW - Cyclosporine

KW - Renal function

KW - Sirolimus

KW - Target of rapamycin (TOR) inhibitors

UR - http://www.scopus.com/inward/record.url?scp=0034810074&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034810074&partnerID=8YFLogxK

M3 - Article

VL - 38

JO - American Journal of Kidney Diseases

JF - American Journal of Kidney Diseases

SN - 0272-6386

IS - 4 SUPPL. 2

ER -